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Abstract
In 2007, an extensive contact screening investigation into onward transmission of tuberculosis was instigated at a hospital
in Northern Ireland following diagnosis of pulmonary multi-drug resistant TB in a healthcare worker. Interferon gamma
release assays (IGRAs) were used to test 333 patients and 98 staff. We investigated for evidence of onward transmission and
recent infection based on analysis of clinical, demographic and IGRA data. We also described within-patient variability of
IGRA results. Among patients and staff, increasing age of patients was the only factor associated with IGRA positivity.
Greatest within-subject variability of IU/mL in serially-tested patients/staff was seen in those with a positive IGRA test and
this did not correlate with increased exposure to the index case. IGRA positivity being largely explained by increasing age in
patients and previous TB contact in staff lends weight to the conclusion that IGRA positivity reflected previous infection
rather than recent transmission.
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Introduction
Tuberculosis (TB) is a leading cause of global morbidity and
mortality. The global effort to control TB is under immense threat
from drug resistance [1]. Since its emergence in the 1990s,
multidrug resistant (MDR-TB) - defined as strains resistant to first-
line drugs Isoniazid and Rifampicin, has become an important
public health problem in many countries. In the UK, while MDR-
TB still remains relatively uncommon, accounting for less than 2%
of TB cases [2], the diagnosis of such patients leads to extensive
investigation to ascertain whether transmission has occurred [3].
Contacts of MDR-TB cases are however, not usually treated for
latent infection due to the absence of effective drug treatment [4].
In June 2007, an extensive contact screening investigation into
onward transmission of TB was instigated at a hospital in
Northern Ireland following the diagnosis of pulmonary MDR-
TB in a healthcare worker. Northern Ireland accounted for ,1%
(n=66) of total UK cases in 2007; a rate of 3.8 per 100,000 [2].
The proportion of all notified cases that were diagnosed in
healthcare workers in Northern Ireland rose from 1% in 1997 to
12% in 2007 [5].
The contact investigation made use of QuantiFERONH-TB
Gold In-Tube (Cellestis Ltd, Carnegie, Australia) interferon gamma
release assays (IGRAs) to test 333 patients and 98 staff members.
Many of the patients screened had a significant co morbidity
including several diseases that increase the probability of developing
active TB. IGRAs measure in vitro interferon gamma production
following stimulation of T-cells by challenge from TB antigens
produced from the region of difference present in the Mycobacterium
tuberculosis complex genome, but not the genomes of Mycobacterium
bovis BCG or the majority of environmental mycobacteria [6].
Based on the observation that the assays measure interferon
produced by a subset of effector memory T-cells which are present
during current infection [7,8], it has been hypothesised that IGRA
positivity implies recent infection [7]. However, currently there is
no evidence that available IGRAs distinguish active from latent
infection [9,8] We hypothesised that if IGRA positivity uniquely
represents recent infection, then among a cohort of untreated
contacts, a small proportion of IGRA positive immunocompro-
mised individuals will progress to active TB irrespective of their
age. If, however, IGRAs largely represent prior exposure then
increasing age will correlate with the test positivity. The results of
the investigation and two years of follow-up allowed us to
investigate: (1) whether there is evidence of onward transmission
resulting from this incident and, if so, (2) whether individuals
testing IGRA positive are likely to have been recently infected
based on analysis of the IGRA results. We also described within-
patient variability of IGRA results.
Methods
Patient population and assessment
All eligible contacts who were immunocompromised (determined
using pre-specified criteria) and housed in the same ward that the
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immunocompromised persons of 1189 in-patients was undertaken on
the basis of their susceptibility to progress to active TB and degree of
exposure to the index case, determined from shift rotas and
admissions data. Pre-specified criteria to determine eligible patients,
using a list of conditions causing immuno-deficiency (including: HIV
infection, diabetes, chronic renal failure, transplant patients, cancer
patients, immunosuppressive therapy - for steroids, over 4 weeks
therapy with at least 20 mg daily was used as an approximate guide)
and therefore an increased risk of progressing from latent to active
disease was used. Screening of patients was carried out by means of
one to three QuantiFERONH-TB Gold In-Tube IGRAs, carried out
six to eight weeks apart. Laboratory tests were conducted in the
Clinical Pathology Accreditation (UK) Ltd-accredited National
Reference laboratory in accordance withthemanufacturer’s(Cellestis
Ltd, Carnegie, Australia) recommendations. All tests results have
been validated using built-in internal quality control criteria.
Follow- up
Patients whose initial test was indeterminate but whose second
test returned a negative result were regarded as not infected and
no further action was taken (see Figure 1). Of patients who were
indeterminate on two tests six to eight weeks apart, or negative on
the first test and indeterminate on a second, those with a previous
history of TB; those with a visible healed tissue on chest x-ray; and
those with old calcified disease on chest x-ray were excluded from
active further follow-up. The case notes and available radiology
were reviewed for all patients with a positive IGRA blood test, and
they were followed-up as though they had recent infection. They
were kept under out-patient department review for over two years
since last possible contact with the index case (the period over
which they are at greatest risk of progression to active disease)
ending August 2009, after which they were discharged with letters
sent to their General Practitioners. Over this period, chest x-rays
were taken at intervals of: 6–8 months; 16–18 months; and at two
years. Provision was made for review on request if they developed
symptoms of TB. No chemoprophylaxis was offered.
Staff
Ninety-eight staff identified from shift rotas as having been in
contact with the index case were screened by single IGRA and,
where aged less than 36 years with no history of BCG, a Mantoux
tuberculin skin test (TST).
Long term surveillance
No further screening was scheduled to be undertaken, subject to
review if any active cases of TB developed among the cohort. The
regional Centre for Disease Surveillance and Control was
requested to notify the hospital trust, should any case of MDR-
TB be identified in Northern Ireland, in order to investigate
possible links with the hospital incident. In addition, patients
excluded from active follow-up were searched for in the national
MDR-TB register to determine if any progressed to active TB.
Analysis
Clinical and demographic details were collected for staff and
patients by the incident management team as part of the screening
exercise, and retrospectively using staff records, interviews and
patient charts. Proportions were compared using Pearson’s chi-
square and means using the t-test. Univariate and multivariable
logistic regression was carried out and odds ratios and 95%
confidence intervals presented. Analysis was carried out using
STATA version 11.
Ethics
The Health Protection Agency (HPA) has the right under
Section 60 of the NHS Act 2006 and approval from the National
Information Governance Board to hold and analyse national
surveillance data for the purposes of protecting public health and
for infectious disease surveillance, as such there was no
requirement to approach a separate ethics committee.
Results
Among 333 patients, 30 (9.01%) had a positive IGRA test, and
41 (12.31%) had an indeterminate result, while seven of 98 staff
tested were positive and one had an indeterminate test. The
median age of patients was 65 years (inter-quartile range 48–76)
and 54.7% were male. Staff had a lower median age (41 years,
inter-quartile range 33–46) and 8.16% were male. Only one
patient converted from IGRA negative to IGRA positive,
however, they later reverted (patient 3 in Figure 2c: conversion
plus known exposure to the index case could potentially be
interpreted as indicative of recent transmission). This patient had 4
days potential exposure to the index case. Patients 1 and 2 (also
Figure 2c, with 2 days and 15 days exposure respectively, and
positive interpretative results) also reverted. No patient or staff
member has been identified with active TB up to 1 June 2010
which is three years after last possible exposure to the index case.
Association between patient characteristics and latent
infection
Three hundred and thirty-three patients were identified for
contact screening (Table 1). This population had a roughly equal
gender split and approximately half (53%) had a co morbidity/use
of immunosuppressive or steroid drugs. Five patients were known
to have a history of TB and one had a family history of TB; two of
these tested IGRA positive. Days of exposure to the index case
ranged from 0–36 days (median=1). Table 1 shows demographic
and clinical characteristics among staff and patients, and
association with IGRA results.
Table 2 shows that exposure to the index case did not appear to
increase the likelihood of testing positive (p=0.293). Increasing
age was the only variable which carried significant risk of testing
IGRA positive (OR 4.12, 95% confidence interval 1.63–10.42,
p=0.003), which was further supported by a test for trend
(P=,0.0005). No other factors analysed were significant. Age
remained the only significant variable (OR 4.74, 95% confidence
interval 1.84–12.25, p=0.001) after fully adjusting for gender,
days potential exposure to the index case and whether or not the
patients were immunocompromised through multivariate analysis.
Figure 1. Patient follow-up.
doi:10.1371/journal.pone.0020770.g001
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infection
Table 1 shows the characteristics of staff by IGRA result. The
majority (6/7) of IGRA-positive staff were UK-born, and all were
from Western European countries of low national TB burden (the
UK and Germany). Forty-three percent (3/7) of the IGRA-
positive staff were known to have had previous contact with a TB
case compared to the 18% of staff who tested negative, however
this was not statistically significant (OR 3.33, CI 0 .68–16.36,
p=0.139). Two staff aged 35 or under with an overall positive
IGRA result did not have a concordant TST result; both tested
negative. Among staff members who had had BCG, vaccination at
school, age was strongly associated with testing negative (OR 0.08,
CI 0.08–0.53, p=0.001). Comparison of the proportions of staff
testing positive with or without having had TST administered as
part of their screening suggest there was no significant difference in
this case between the two groups (p=0.194). This indicates the
absence of boosting of IGRA results by TST.
Within-patient variability
123 staff and patients were serially IGRA tested (38 staff were
tested twice and, of 85 patients, 73 were tested twice and 12 were
tested three times). Due to small numbers, the two cohorts were
amalgamated. Most staff were Northern Ireland-born so were
likely to have had similar low exposure to TB as the patients
(though we acknowledge that, due to their profession, they may be
at slightly elevated risk of exposure). Though the median within-
subject variability was low (0.03 IU/mL), a wide range (0–
14.26 IU/mL) was observed. Greatest fluctuation was seen in
those who had at least one positive result and were, therefore,
assigned an overall interpretative result of testing positive for latent
TB infection. Figure 2a shows the data for patients who had
multiple tests.
There were three serially-tested patients given an overall
interpretive value of being IGRA-positive who demonstrated
reversion or conversion-reversion (Figure 2c). Patient 1 had 2 days
recorded exposure to the index case; Patient 2 had 15 days
exposure; and Patient 3 had 4 days exposure. All three positive test
results were close to the 0.35 IU/mL cut-off value and were
followed by a much lower reading.
Discussion
The study found that, among patients, increasing age was the
only factor associated with IGRA positivity. No other variables
were significantly associated with IGRA results among patients or
staff. No cases of active TB were reported despite two years of
active monitoring and screening of IGRA positive persons and
passive follow-up of an immunocompromised population. The
greatest within-subject variability of IGRA readings was seen in
those with a positive test and this did not correlate with increased
exposure to the index case.
The observed association with increasing age as the only
independent risk factor in the multivariable model and the lack of
progression to active disease amongst the patient cohort suggests
that remote exposure, when TB was more prevalent in Northern
Ireland is a likely explanation. For example, between 1950 and
1954 an average of 1732 cases were notified in Northern Ireland
[10], compared to 66 notifications in 2007 [2]. An alternative
explanation is that IGRA positivity was influenced by place of
birth and ethnic origin, variables not collected in this investigation
because the patient population was all white and predominantly
UK-born. Advancing age also increases the likelihood of exposure
Figure 2. Study IGRA results. A, Interpretative patient IGRA result by days exposure to index case. *Serially IGRA-tested patients only. B, Within-
subject variability of patients by days exposure to index case. C, Patient conversion/reversion.
doi:10.1371/journal.pone.0020770.g002
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environmental mycobacteria, some of which cross-react with
IGRA tests (Mycobacterium kansasii, Mycobacterium szulgai and
Mycobacterium marinum), despite the high specificity of IGRAs for
the Mycobacterium tuberculosis complex. Furthermore, the lack of
association between IGRA positivity and exposure to the index
case is consistent with this observation.
A review on the role of IGRAs in healthcare workers found
poor levels of concordance between IGRA and TST results unless
a study is being undertaken in a country of high TB incidence, but
that IGRAs correlated better with TB exposure [11]. There were
two staff members aged less than 36 years, with a positive IGRA
and negative TST result, of which one had had BCG. TST
administration has in some cases been observed to have a boosting
effect on subsequent IGRA tests [12], however, no significant
difference was found in IGRA results between TST positive and
TST negative individuals, where a TST result was known. It has
been proposed that many TST negative, IGRA positive results
may be attributed to the individual having been remotely exposed
to TB many years previously, hence the waning TST response [9].
Despite a lack of statistical significance, among staff previous TB
contact seems a compelling explanation for the majority of positive
interpretative IGRA results; 42.9% had had a known previous
contact in this group compared to 17.8% of those testing negative.
Of course, the true numbers of staff (and patients) who have come
into contact with humans/animals with tuberculosis is unknown.
Swindells et al., found that positive QFT IGRA results in
healthcare workers were generally associated with length of time
in employment, or profession, used as a proxy measure of their
increased likelihood of occupational exposure to TB [11].
School-age vaccination with BCG was found to be significantly
associated with testing IGRA negative. Under the school
vaccination programme, children are TST screened for current
latent TB infection. Those testing positive, and therefore
previously infected, are not vaccinated and those testing negative
were given BCG. Two of seven staff who tested positive had had
school vaccination, the rest were never vaccinated and were
therefore likely to have had prior exposure to TB.
In total there were 37 staff/patients who tested IGRA positive.
Forty-six percent of these were immunocompromised. Due to the
MDR-TB status of the index case none of these were placed on
Table 1. Demographic and clinical characteristics of staff
(n=98) and patients (n=333).
Characteristic IGRA positive IGRA negative
n( % ) n( % )
Staff
Characteristic
Total 7 90
No. (%) male 1 (14.3) 7 (7.8)
Age (yr)
Median 45 41
IQR 32.5–52 33–46
Country of birth [No. (%)]
UK 6 (85.7) 79 (87.8)
Non-UK (Canada, Germany,
Philippines, Republic of Ireland)
1 (14.3) 10 (11.1)
Unknown 0 (0) 1 (1.1)
BCG vaccination status [No. (%)]
Vaccinated 2 (28.6) 76 (84.4)
Unknown 0 6 (6.7)
TST (where age ,=35) [No. (%)]
Total 2 32
Positive (.=15 mm induration) 0 6 (18.8)
Unknown 0 2 (6.25)
Co-morbidities [No. (%)]
Immunocompromised 0 0
HIV 0 0
Diabetes 1 (14.3) 0
Previous TB contact 3 (42.9) 16 (17.8)
Patients
Characteristic IGRA positive IGRA negative
Total 30 262
No. (%) male 17 (56.7) 145 (55.3)
Age (yr)
Median 70.5 64
IQR 65.5–74 45–77
Co-morbidities [No. (%)]
Diabetes 7 (23.3) 64 (24.4)
Cancer 8 (26.7) 69 (26.3)
Immunosuppressive drugs/
chemotherapy*
1 (3.3) 42 (16)
Steroids 3 (10) 41 (15.6)
Unknown 1 (3.3) 8 (3.1)
Any co-morbidity 16 (53.3) 165 (63)
doi:10.1371/journal.pone.0020770.t001
Table 2. Odds ratios and p-values for selected demographic
and clinical factors of patients with a determinate
interpretative IGRA results (n=292).
Characteristic IGRA OR (95% CI)
Positive n/N (%)
or mean (IQR)
Days of exposure (SD) Positive 3.93 (4.75) 1.04 (0.97–1.11)
Negative* 2.95 (3)
Gender Male 17/162 (10.49) 1.01 (0.47–2.16)
Female 13/130 (10)
Age group 0–64 6/139 (4.32)
65–74 24/153 (15.69) 4.12 (1.63–10.42)
Steroids Yes 3/44 (6.82) 0.60 (0.17–2.07)
No 26/239 (10.88)
Diabetes Yes 7/71 (9.86) 0.94 (0.38–2.30)
No 22/211 (10.43)
Cancer Yes 8/77 (10.39) 1.02 (0.43–2.41)
No 21/206(10.19)
Immunosuppressive
drugs/chemotherapy**
Yes 1/43 (2.33) 0.18 (0.02–1.36)
No 28/240 (11.67)
*Where known (4 values missing).
**Anti-cancer chemotherapy within 4 weeks of exposure to index case or
ongoing chemotherapy only.
doi:10.1371/journal.pone.0020770.t002
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cohort (2/37 individuals) to progress to active disease if they had
been recently infected. After two years of follow-up no case of
active disease has been reported further supporting hypothesis that
IGRA positive results, at least in this cohort, reflects previous
exposure to mycobacteria.
At present data is lacking on the amount of variation that might
be expected where individuals are repeatedly IGRA tested,
however, significant variation has been reported [12,13]. This
has ramifications for interpretation of single IGRA values
(especially those close to the cut-off point) and for thresholds of
reversion and conversion [12]. In this dataset, the wide range of
IGRA readings derived from serially-tested individuals and the
fact that those individuals with a positive IGRA result show the
greatest variation makes identification of true-positive results
problematic. Results of our study support previous limited
evidence of greater variability within positive test results [7].
The changes observed, including reversions in three patients,
could be explained by within-subject non-specific biological
variability around the cut-off point rather than genuine changes
of infection status. These findings are congruent with a recent
systematic review on use of IGRAs in screening of healthcare
workers, where, of 10 studies using IGRAs for serial testing, all
showed great variation in conversion and reversion rates,
confounded by a lack of data on optimal cut-off points for serial
testing [13].
Most limitations of this study reflect the difficulties involved in
carrying out a high-profile and large-scale contact screening
investigation based upon a dynamic population. For instance, the
collection of duration of exposure was not done prospectively and
despite the use of shift duty hours of staff and patient hospital
admission dates as a guide, there is likely to be some
misclassification. Variables such as previous TB contact rely on
recall by the staff or patients and are therefore subject to bias.
Other limitations include completeness of medical and admissions
records. The small number of IGRA positive individuals among
staff also limited the ability of this study to detect factors associated
with latent infection.
The absence of TB cases in this cohort and the association with
increasing age, would suggest that the universal treatment of
casual contacts with a positive IGRA result, especially among
older contacts may not be appropriate. These individuals could
have acquired latent TB infection when they were younger and
adverse effects of chemoprophylaxis are likely to be more
common.
Currently, where the index case is not MDR, it is considered
unacceptable to disregard a positive IGRA result and consider-
ation is given to treating the patient for latent TB [14].
Furthermore, the significant variability among those testing
positive in this contact screening exercise casts doubt on whether
single positive IGRA results near the cut-off point or, particularly,
positive results followed by reversion, should be considered true-
positives. Further predictive value studies with serial testing of
participants are needed to investigate this. It has recently been
hypothesised that patients remaining persistently positive or that
show stable conversion to positive following serial testing will be
more likely to progress to active TB [15].
Transmission events from the index case to other staff members
or patients are unlikely. No cases of active disease have been
reported over two years since the contact screening exercise took
place. Each cohort screened had one compelling explanatory
variable: age in patients and previous contact in staff which, in this
dataset, lends weight to the conclusion that IGRA positivity can
not be used as an indicator of recent transmission. Widest
variation was seen in IGRA readings from individuals who had
multiple readings. Fluctuation and reversion from positive results
close to the cut-off point means that positive results should at least
be interpreted with caution.
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